Untitled

Hurley, Susan F; Matthews, Jane P.

doi:10.1186/1478-7547-5-2

Cited by 39 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We compared the life expectancy of the general French population in 2000 [ 48 ] and the time onset of chronic illness [ 8 ] in the general population generated by the model. Second, we compared the results of our model to a similar Markov model study conducted in Australia [ 49 ] also in addition to the actual results of the Stop Smoking Service, a fully covered smoking cessation program already implemented by the NHS in the UK [ 50 ]. We incorporated the specific parameters of both cases (cessation rate, participation rate, number and frequency of attempts) into our model to test external validity.…”

Section: Methodsmentioning

confidence: 99%

Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases

et al. 2016

View full text Add to dashboard Cite

ContextIn France more than 70,000 deaths from diseases related to smoking are recorded each year, and since 2005 prevalence of tobacco has increased. Providing free access to smoking cessation treatment would reduce this burden. The aim of our study was to estimate the incremental cost-effectiveness ratios (ICER) of providing free access to cessation treatment taking into account the cost offsets associated with the reduction of the three main diseases related to smoking: lung cancer, chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD). To measure the financial impact of such a measure we also conducted a probabilistic budget impact analysis.Methods and FindingsWe performed a cost-effectiveness analysis using a Markov state-transition model that compared free access to cessation treatment to the existing coverage of €50 provided by the French statutory health insurance, taking into account the cost offsets among current French smokers aged 15–75 years. Our results were expressed by the incremental cost-effectiveness ratio in 2009 Euros per life year gained (LYG) at the lifetime horizon. We estimated a base case scenario and carried out a Monte Carlo sensitivity analysis to account for uncertainty. Assuming a participation rate of 7.3%, the ICER value for free access to cessation treatment was €3,868 per LYG in the base case. The variation of parameters provided a range of ICER values from -€736 to €15,715 per LYG. In 99% of cases, the ICER for full coverage was lower than €11,187 per LYG. The probabilistic budget impact analysis showed that the potential cost saving for lung cancer, COPD and CVD ranges from €15 million to €215 million at the five-year horizon for an initial cessation treatment cost of €125 million to €421 million.ConclusionThe results suggest that providing medical support to smokers in their attempts to quit is very cost-effective and may even result in cost savings.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Potential cost offsets from a reduction in health care costs of quitters were used to calculate net intervention costs. Cost offsets were based on the Quit Benefits Model, which is a tool developed in Australia to predict the difference in health care costs of smokers and nonsmokers for males and females by age group after 10 years follow-up [20]. This follow-up period was considered long enough to show the beneficial impact of quitting, but short enough to remain within the time frame of policy makers.…”

Section: Methodsmentioning

confidence: 99%

Internet-Based Photoaging Within Australian Pharmacies to Promote Smoking Cessation: Randomized Controlled Trial

Burford¹,

Jiwa²,

Carter³

et al. 2013

J Med Internet Res

109

View full text Add to dashboard Cite

BackgroundTobacco smoking leads to death or disability and a drain on national resources. The literature suggests that cigarette smoking continues to be a major modifiable risk factor for a variety of diseases and that smokers aged 18-30 years are relatively resistant to antismoking messages due to their widely held belief that they will not be lifelong smokers.ObjectiveTo conduct a randomized controlled trial (RCT) of a computer-generated photoaging intervention to promote smoking cessation among young adult smokers within a community pharmacy setting.MethodsA trial was designed with 80% power based on the effect size observed in a published pilot study; 160 subjects were recruited (80 allocated to the control group and 80 to the intervention group) from 8 metropolitan community pharmacies located around Perth city center in Western Australia. All participants received standardized smoking cessation advice. The intervention group participants were also digitally photoaged by using the Internet-based APRIL Face Aging software so they could preview images of themselves as a lifelong smoker and as a nonsmoker. Due to the nature of the intervention, the participants and researcher could not be blinded to the study. The main outcome measure was quit attempts at 6-month follow-up, both self-reported and biochemically validated through testing for carbon monoxide (CO), and nicotine dependence assessed via the Fagerström scale.ResultsAt 6-month follow-up, 5 of 80 control group participants (6.3%) suggested they had quit smoking, but only 1 of 80 control group participants (1.3%) consented to, and was confirmed by, CO validation. In the intervention group, 22 of 80 participants (27.5%) reported quitting, with 11 of 80 participants (13.8%) confirmed by CO testing. This difference in biochemically confirmed quit attempts was statistically significant (χ2 1=9.0, P=.003). A repeated measures analysis suggested the average intervention group smoking dependence score had also significantly dropped compared to control participants (P<.001). These differences remained statistically significant after adjustment for small differences in gender distribution and nicotine dependence between the groups. The mean cost of implementing the intervention was estimated at AU $5.79 per participant. The incremental cost-effectiveness ratio was AU $46 per additional quitter. The mean cost that participants indicated they were willing to pay for the digital aging service was AU $20.25 (SD 15.32).ConclusionsDemonstrating the detrimental effects on facial physical appearance by using a computer-generated simulation may be both effective and cost-effective at persuading young adult smokers to quit.Trial RegistrationAustralian New Zealand Clinical Trials Registry: ACTRN12609000885291; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12609000885291 (Archived by WebCite at http://www.webcitation.org/6F2kMt3kC)

show abstract

“…A similar population-based model was presented in Magnus et al , 49 while a similar Markov model was presented in Hurley and Matthews. 44 …”

Section: Discussionmentioning

confidence: 99%

“…For ischaemic heart disease, stroke, COPD and lung cancer, we used the estimations presented in Hurley and Matthews. 44 We assumed that risks for ex-smokers for diabetes mellitus follow the pattern of CVD decrease while the risks for other cancer diagnoses decrease linearly during 20 years. The QALY weights were used to describe the losses in health-related quality of life (QoL) due to the diseases.…”

Section: Methodsmentioning

confidence: 99%

Economic evaluation of a brief counselling for smoking cessation in dentistry: a case study comparing two health economic models

Virtanen

Galanti

Johansson³

et al. 2017

BMJ Open

View full text Add to dashboard Cite

ObjectivesThis study aimed to compare the cost-effectiveness estimates of a brief counselling of smoking cessation in dentistry by using two different health economic models.Design and outcome measuresIntervention effectiveness was estimated in a cluster randomised controlled trial. The number of quitters was estimated based on 7-day abstinence and on smoking reduction at follow-up. Health economic evaluation was performed using two models: (1) a population-based model employing potential impact fractions and (2) a Markov model estimating the cost-effectiveness of the intervention for the actual participants. The evaluation was performed from healthcare and societal perspectives, and health gains were expressed in quality-adjusted life-years (QALYs).SettingDental clinics in Sweden.Participants205 Swedish smokers aged 20–75 years.InterventionsA brief, structured behavioural intervention was compared with ‘usual care’.ResultsThe cost per quitter was US$552 in the intervention and US$522 in the ‘usual care’ condition. The net saving estimated with the population-based model was US$17.3 million for intervention and US$49.9 million for ‘usual care’, with health gains of 1428 QALYs and 2369 QALYs, respectively, for the whole Swedish population during 10 years. The intervention was thus dominated by ‘usual care’. The reverse was true when using the Markov model, showing net societal savings of US$71 000 for the intervention and US$57000 for ‘usual care’, with gains of 5.42 QALYs and 4.74 QALYs, respectively, for lifelong quitters.ConclusionThe comparison of intervention and ‘usual care’ derived from small-scale studies may be highly sensitive to the choice of the model used to calculate cost-effectiveness.Trial registrationThe cluster randomised trial is registered in the ISRCTN register of controlled trials with identification number ISRCTN50627997.

show abstract

Untitled

Abstract: Background: In response to the lack of comprehensive information about the health and economic benefits of quitting smoking for Australians, we developed the Quit Benefits Model (QBM).

Cited by 39 publications

References 37 publications

Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases

Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases

Internet-Based Photoaging Within Australian Pharmacies to Promote Smoking Cessation: Randomized Controlled Trial

Economic evaluation of a brief counselling for smoking cessation in dentistry: a case study comparing two health economic models

Contact Info

Product

Resources

About